Literature DB >> 23902145

The role of antimicrobial stewardship in curbing carbapenem resistance.

Christopher Bogan1, Dror Marchaim.   

Abstract

Antimicrobial resistance is a continuing, growing, worldwide iatrogenic complication of modern medical care. Carbapenem resistance among certain pathogens poses a significant challenge. In order to reduce the spread of these nearly untreatable pathogens, preventative efforts should be directed at reducing patient-to-patient transmission and preventing the emergence of resistance among susceptible strains. One theoretical intervention to reduce the emergence of resistance is establishing and strictly adhering to an antimicrobial stewardship program. However, data pertaining to the direct effect of stewardship in curtailing carbapenem resistance among epidemiologically significant organisms are scarce. In this report, we review the potential biases associated with data interpretation in this research field, and we review the data pertaining to the impact of stewardship in curbing carbapenem resistance in three significant groups of pathogens: Pseudomonas aeruginosa, Enterobacteriaceae and Acinetobacter baumannii.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23902145     DOI: 10.2217/fmb.13.73

Source DB:  PubMed          Journal:  Future Microbiol        ISSN: 1746-0913            Impact factor:   3.165


  9 in total

1.  Evaluation of effects of an operational multidisciplinary team on antibiotic use in the medium to long term at a French university hospital.

Authors:  Béatrice Demoré; Pauline Humbert; Emmanuelle Boschetti; Sibylle Bevilacqua; Isabelle Clerc-Urmès; Thierry May; Céline Pulcini; Nathalie Thilly
Journal:  Int J Clin Pharm       Date:  2017-07-29

Review 2.  Screening for carbapenem-resistant Enterobacteriaceae: Who, When, and How?

Authors:  Sandra S Richter; Dror Marchaim
Journal:  Virulence       Date:  2016-11-04       Impact factor: 5.882

3.  Clinical and Epidemiological Significance of Carbapenem Resistance in Acinetobacter baumannii Infections.

Authors:  Ruthy Tal-Jasper; David E Katz; Nadav Amrami; Dor Ravid; Dori Avivi; Ronit Zaidenstein; Tsilia Lazarovitch; Mor Dadon; Keith S Kaye; Dror Marchaim
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

4.  Impact of clinical pharmacist intervention on antimicrobial use in a small 164-bed hospital.

Authors:  Pedro Mas-Morey; Alfonso Ballesteros-Fernández; Elisabet Sanmartin-Mestre; Marta Valle
Journal:  Eur J Hosp Pharm       Date:  2017-11-01

5.  Infection control and risk factors for acquisition of carbapenemase-producing enterobacteriaceae. A 5 year (2011-2016) case-control study.

Authors:  Luigi Segagni Lusignani; Elisabeth Presterl; Beata Zatorska; Miriam Van den Nest; Magda Diab-Elschahawi
Journal:  Antimicrob Resist Infect Control       Date:  2020-01-17       Impact factor: 4.887

6.  Risk Factors for a Hospital-Acquired Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infection: A Five-Year Retrospective Study.

Authors:  Zubai Cao; Chengcheng Yue; Qinxiang Kong; Yanyan Liu; Jiabin Li
Journal:  Infect Drug Resist       Date:  2022-02-25       Impact factor: 4.003

7.  The Impact of Antimicrobial Stewardship and Infection Control Interventions on Acinetobacter baumannii Resistance Rates in the ICU of a Tertiary Care Center in Lebanon.

Authors:  Nesrine A Rizk; Nada Zahreddine; Nisrine Haddad; Rihab Ahmadieh; Audra Hannun; Souad Bou Harb; Sara F Haddad; Rony M Zeenny; Souha S Kanj
Journal:  Antibiotics (Basel)       Date:  2022-07-07

8.  Evaluating a Pharmacy-Driven 72-Hour Antibiotic Monitoring Program Implemented in a Community Hospital.

Authors:  Vishal Patel; Shaina Doyen
Journal:  Hosp Pharm       Date:  2019-08-06

9.  Implementation of an antimicrobial stewardship programme and reduction in carbapenemase-producing Enterobacterales in an Australian local health district.

Authors:  Kimberly Cipko; Jose Cuenca; Erica Wales; Joanna Harris; Stuart Bond; Peter Newton; Spiros Miyakis
Journal:  JAC Antimicrob Resist       Date:  2020-07-13
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.